Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Eli Lilly · Phase 1 · Not yet recruiting · Enrollment 60

NCT07765511

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Macupatide + placebon/rn/rn/rn/r
Eloralintide + placebon/rn/rn/rn/r
Macupatide Dose A + Eloralintiden/rn/rn/rn/r
Macupatide Dose B + Eloralintiden/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Macupatide + placebo: endpoint not reported
  • Eloralintide + placebo: endpoint not reported
  • Macupatide Dose A + Eloralintide: endpoint not reported
  • Macupatide Dose B + Eloralintide: endpoint not reported
  • Placebo: endpoint not reported